Risk assessment of post-discharge mortality among recently hospitalized Medicare heart failure patients with reduced or preserved ejection fraction

References

• Cheng RK, Cox M, Neely ML, et al. Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. Am Heart J. 2014;168(5):721–730.
   PubMed Web of Science ®Google Scholar
• Loop MS, Van Dyke MK, Chen L, et al. Comparison of length of stay, 30-day mortality, and 30-day readmission rates in Medicare patients with heart failure and with reduced versus preserved ejection fraction. Am J Cardiol. 2016;118(1):79–85.
   PubMed Web of Science ®Google Scholar
• Nichols GA, Reynolds K, Kimes TM, et al. Comparison of risk of re-hospitalization, all-cause mortality, and medical care resource utilization in patients with heart failure and preserved versus reduced ejection fraction. Am J Cardiol. 2015;116(7):1088–1092.
   PubMed Web of Science ®Google Scholar
• Coles AH, Fisher K, Darling C, et al. Long-term survival for patients with acute decompensated heart failure according to ejection fraction findings. Am J Cardiol. 2014;114(6):862–868.
   PubMed Web of Science ®Google Scholar
• Caughey MC, Sueta CA, Stearns SC, et al. Recurrent acute decompensated heart failure admissions for patients with reduced versus preserved ejection fraction (from the atherosclerosis risk in communities study). Am J Cardiol. 2018;122(1):108–114.
   PubMed Web of Science ®Google Scholar
• Senni M, Paulus WJ, Gavazzi A, et al. New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. Eur Heart J. 2014;35(40):2797–2815.
   PubMed Web of Science ®Google Scholar
• Vorilhon C, Jean F, Mulliez A, et al. Optimized management of heart failure patients aged 80 years or more improves outcomes versus usual care: The HF80 randomized trial. Arch Cardiovasc Dis. 2016;109(12):667–678.
   PubMed Web of Science ®Google Scholar
• Auble TE, Hsieh M, Gardner W, et al. A prediction rule to identify low-risk patients with heart failure. Acad Emerg Med. 2005;12(6):514–521.
   PubMed Web of Science ®Google Scholar
• Collins SP, Jenkins CA, Harrell FE Jr, et al. Identification of emergency department patients with acute heart failure at low risk for 30-day adverse events: the STRATIFY decision tool. JACC Heart Fail. 2015;3(10):737–747.
   PubMed Web of Science ®Google Scholar
• Felker GM, Leimberger JD, Califf RM, et al. Risk stratification after hospitalization for decompensated heart failure. J Card Fail. 2004;10(6):460–466.
   PubMed Web of Science ®Google Scholar
• Khazanie P, Heizer GM, Hasselblad V, et al. Predictors of clinical outcomes in acute decompensated heart failure: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure outcome models. Am Heart J. 2015;170(2):290–297.
   PubMed Web of Science ®Google Scholar
• Lee DS, Austin PC, Rouleau JL, et al. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA. 2003;290(19):2581–2587.
   PubMed Web of Science ®Google Scholar
• O’Connor CM, Mentz RJ, Cotter G, et al. The PROTECT in-hospital risk model: 7-day outcome in patients hospitalized with acute heart failure and renal dysfunction. Eur J Heart Fail. 2012;14(6):605–612.
   PubMed Web of Science ®Google Scholar
• Postmus D, van Veldhuisen DJ, Jaarsma T, et al. The COACH risk engine: a multistate model for predicting survival and hospitalization in patients with heart failure. Eur J Heart Fail. 2012;14(2):168–175.
   PubMed Web of Science ®Google Scholar
• Salah K, Kok WE, Eurlings LW, et al. A novel discharge risk model for patients hospitalised for acute decompensated heart failure incorporating N-terminal pro-B-type natriuretic peptide levels: a European coLlaboration on Acute decompeNsated Heart Failure: ELAN-HF Score. Heart. 2014;100(2):115–125.
   PubMed Web of Science ®Google Scholar
• Xanthopoulos A, Giamouzis G, Tryposkiadis K, et al. A simple score for early risk stratification in acute heart failure. Int J Cardiol. 2017;230:248–254.
   PubMed Web of Science ®Google Scholar
• Davison BA, Metra M, Senger S, et al. Patient journey after admission for acute heart failure: length of stay, 30-day readmission and 90-day mortality. Eur J Heart Fail. 2016;18(8):1041–1050.
   PubMed Web of Science ®Google Scholar
• Komajda M, Carson PE, Hetzel S, et al. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circ Heart Fail. 2011;4(1):27–35.
   PubMed Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147–e239.
   PubMed Web of Science ®Google Scholar
• Lee DS, Gona P, Vasan RS, et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham heart study of the national heart, lung, and blood institute. Circulation. 2009;119(24):3070–3077.
   PubMed Web of Science ®Google Scholar
• Bovitz T, Gilbertson DT, Herzog CA. Administrative data and the philosopher’s stone: turning heart failure claims data into quantitative assessment of left ventricular ejection fraction. Am J Med. 2016;129(2):223–225.
   PubMed Web of Science ®Google Scholar
• Dusenberry MW, Brown CK, Brewer KL. Artificial neural networks: predicting head CT findings in elderly patients presenting with minor head injury after a fall. Am J Emerg Med. 2017;35(2):260–267.
   PubMed Web of Science ®Google Scholar
• Givargis S, Karimi H. A basic neural traffic noise prediction model for Tehran’s roads. J Environ Manage. 2010;91(12):2529–2534.
   PubMed Web of Science ®Google Scholar
• Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation. 2006;113(11):1424–1433.
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Packer M, Desai AS, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004.
   PubMed Web of Science ®Google Scholar
• Morrow DA, Velazquez EJ, DeVore AD, et al. Clinical outcomes in patients with acute decompensated heart failure randomly assigned to sacubitril/valsartan or enalapril in the PIONEER-HF trial. Circulation. 2019;139(19):2285.
   PubMed Web of Science ®Google Scholar
• Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376(9744):875–885.
   PubMed Web of Science ®Google Scholar